Loading clinical trials...
Loading clinical trials...
Phase I, Open Label, Dose Escalating Study to Investigate Safety and Tolerability of Intravesical Application of Trifunctional Anti-EPCAM x Anti-CD3 Antibody Catumaxomab in Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Conditions
Interventions
Catumaxomab
Locations
1
Germany
Urologie Planegg
München, Germany
Start Date
July 7, 2020
Primary Completion Date
December 30, 2022
Completion Date
December 30, 2023
Last Updated
April 5, 2022
NCT07222488
NCT05614739
NCT06441110
NCT06403202
NCT03459846
NCT02489890
Lead Sponsor
Lindis Biotech GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions